Sterling Global Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sterling Global Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$266K	Hold	3,000	–	–	1.48%	18
2018 Q4	$255K	Hold	3,000	–	–	1.3%	16
2018 Q3	$291K	Hold	3,000	–	–	1.27%	20
2018 Q2	$283K	Hold	3,000	–	–	1.83%	16
2018 Q1	$243K	Hold	3,000	–	–	1.14%	22
2017 Q4	$268K	Hold	3,000	–	–	1.13%	21
2017 Q3	$279K	Hold	3,000	–	–	1.14%	24
2017 Q2	$272K	Hold	3,000	–	–	1.3%	20
2017 Q1	$263K	Hold	3,000	–	–	1.27%	19
2016 Q4	$249K	Hold	3,000	–	–	1.01%	19
2016 Q3	$278K	Hold	3,000	–	–	1.03%	18
2016 Q2	$233K	Hold	3,000	–	–	0.89%	17
2016 Q1	$247K	Hold	3,000	–	–	1.26%	16
2015 Q4	$314K	Hold	3,000	–	–	4.98%	8
2015 Q3	$316K	Hold	3,000	–	–	1.74%	9
2015 Q2	$410K	Hold	3,000	–	–	1.38%	8
2015 Q1	$374K	Hold	3,000	–	–	1.14%	11
2014 Q4	$271K	Buy	+3,000	New	+$249K	0.15%	14

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Global Strategies's BMRN Position: Q1 2019 in Review

Sterling Global Strategies held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2019 at 3,000 shares worth $266K. The position accounts for 1.48% of the portfolio, ranked #18.

Sterling Global Strategies first reported a position in BMRN in Q4 2014 and has held it in 18 quarters since. The position peaked at $410K in Q2 2015. 485 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

Sterling Global Strategies held 3,000 shares of BioMarin Pharmaceuticals worth $266K as of Q1 2019.
Sterling Global Strategies left its BioMarin Pharmaceuticals share count unchanged in Q1 2019.
BioMarin Pharmaceuticals made up 1.48% of Sterling Global Strategies's portfolio in Q1 2019, its #18 holding.
Sterling Global Strategies first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 18 quarters since.
Sterling Global Strategies's BioMarin Pharmaceuticals position peaked at $410K in Q2 2015.
485 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Sterling Global Strategies's 13F filing for Q1 2019, filed 15 May 2019.